PMID- 30427510
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1678-4227 (Electronic)
IS  - 0004-282X (Linking)
VI  - 76
IP  - 10
DP  - 2018 Oct
TI  - Multiple sclerosis: disease modifying therapy and the human leukocyte antigen.
PG  - 697-704
LID - S0004-282X2018001000697 [pii]
LID - 10.1590/0004-282X20180103 [doi]
AB  - OBJECTIVE: To investigate the potential relationship between the human leukocyte 
      antigen (HLA) type (class I and II) and the response to several disease-modifying 
      therapies (DMTs) in patients with multiple sclerosis (MS). METHODS: We analyzed 
      clinical data of 87 patients with MS at the beginning and end of each type of DMT 
      including the disease duration, Expanded Disability Status Scale and Multiple 
      Sclerosis Severity Score (MSSS). Genotyping of HLA-DRB1, HLA-DPB1, HLA-DQB1, 
      HLA-A, HLA-B and HLA-C alleles were identified using high-resolution techniques. 
      Statistical correlation between the HLA type and response to DMTs was done using 
      the initial and final MSSS. RESULTS: Statistical relationships (p < 0.05) were 
      found for only 15 of 245 alleles tested. There was a reduction in the MSSS for 
      patients treated with corticosteroids (DRB1*15:01, DPB1*04:01, DQB1*02:01 and 
      DQB1*03:01), azathioprine (DRB1*03:01, DPB1*04:01, DQB1*03:02, DQB1*06:02, 
      HLA-C*07:02), interferon beta-1a 22 mcg (DRB1*11:04, DQB1*03:01 and DQB1*03:02), 
      interferon beta-1a 30 mcg (DPB1*02:01, HLA-C*05:01) and interferon beta-1b 
      (DQB1*02:01). CONCLUSION: These findings suggest a few relationships between the 
      HLA and response to DMTs in the disability for some types of HLA class I and II 
      alleles in a specific subset of MS patients.
FAU - Werneck, Lineu Cesar
AU  - Werneck LC
AD  - Universidade Federal do Parana, Hospital de Clinicas, Servico de Neurologia, 
      Curitiba PR, Brasil.
FAU - Lorenzoni, Paulo Jose
AU  - Lorenzoni PJ
AD  - Universidade Federal do Parana, Hospital de Clinicas, Servico de Neurologia, 
      Curitiba PR, Brasil.
FAU - Kay, Claudia Suemi Kamoi
AU  - Kay CSK
AD  - Universidade Federal do Parana, Hospital de Clinicas, Servico de Neurologia, 
      Curitiba PR, Brasil.
FAU - Scola, Rosana Herminia
AU  - Scola RH
AD  - Universidade Federal do Parana, Hospital de Clinicas, Servico de Neurologia, 
      Curitiba PR, Brasil.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arq Neuropsiquiatr
JT  - Arquivos de neuro-psiquiatria
JID - 0125444
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-D Antigens)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
CIN - Arq Neuropsiquiatr. 2018 Oct;76(10):647-648. PMID: 30427502
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Child
MH  - Disease Progression
MH  - Female
MH  - Gene Frequency/genetics
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - HLA-D Antigens/genetics
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/drug therapy/*genetics
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2018/11/15 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/02/15 00:00 [received]
PHST- 2018/07/10 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
AID - S0004-282X2018001000697 [pii]
AID - 10.1590/0004-282X20180103 [doi]
PST - ppublish
SO  - Arq Neuropsiquiatr. 2018 Oct;76(10):697-704. doi: 10.1590/0004-282X20180103.